Milestone Pharmaceuticals
BioTech/Drugs - Montreal, QC, US
Milestone Pharmaceuticals Employees
Amit Hasija
Chief Financial Officer and Executive Vice President of Corporate Development
Milestone Pharmaceuticals Senior Management
Amit Hasija
Chief Financial Officer and Executive Vice President of Corporate Development
Milestone Pharmaceuticals Details
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. Etripamil is a novel, potent and short-acting calcium channel blocker designed by Milestone and being developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of PSVT as they occur. Milestone is actively recruiting patients for a Phase 3 clinical trial of etripamil for the treatment of PSVT. Milestone plans to initiate a Phase 2 clinical trial in atrial fibrillation, another rapid heart rate condition, and expects to subsequently initiate an additional Phase 2 clinical trial in angina to establish proof-of-concept for the broader use of etripamil.
Milestone Pharmaceuticals Technologies
Email Providers
Outlook
CMS
WP Engine
Fonts
Typekit
Other
Microsoft Office 365
Hosting
Google Cloud Hosting
Search Marketing
Adobe Marketing Cloud